.191 x .23 right now. NGNM: NeoGenomics, Inc. is a clinical testing laboratory that offers genetic and molecular diagnostic testing services to the oncology and perinatology markets. NeoGenomics is headquartered in Fort Myers, FL and services the needs of oncologists, pathologists and hospitals throughout the United States. NGNM currently has an OS of 22,576,975;
This company released big news right at the end of the 3rd quarter of 2005. They do not issue a lot of news releases but they announce operational news right before the end of the quarter and we expect some for this quarter. In their last news release NGNM announced that they had begun some new testing. These results should come out in their 4th quarter filing. With the added testing, again the quarterly growth should be excellent.
Quote: "strong growth continued in the third quarter with testing volumes up over 65.3% during the quarter versus the second quarter of 2005 and up over 420% from the third quarter of 2004. NeoGenomics also announced that during the third quarter, it had begun testing operations in three new areas: breast cancer, bladder cancer and cervical cancer. "
Posted by Raptorsrule on :
I'm trying this one Keith...
Posted by keithsan on :
bid over HOD .20 x .23 now
Posted by keithsan on :
LOL such a low float, no one will sell on the bid.
Posted by keithsan on :
.19 x .22 spread closed and the volume came in...
Posted by Raptorsrule on :
nice action here:)...cmon' baaaybe....
Posted by keithsan on :
5 on the bid .18 thru .183
Posted by stockfever on :
In at 0.19...now let's roll
Posted by keithsan on :
nice price, ask is .209 then .22 then .30...
Posted by stockfever on :
Ask at 0.19 again...who's gonna jump on it?
Posted by stockfever on :
Gone ask 0.215 now
Posted by cruz on :
are you concerned about the cornell relationship?
Posted by cruz on :
not trying to sound like strike1
Posted by keithsan on :
quote:Originally posted by cruz: are you concerned about the cornell relationship?
no, its for 5million shares and from last july. I've never had problems with cornell, i think its been an excuse for crappy stocks.
Posted by stockfever on :
At 0.21 now...looking good
Posted by keithsan on :
drove home, got an ask of .20 then .21 then .30..
Posted by keithsan on :
i have 90k in buys, 3 transactions at .185 for a close.
Posted by stockfever on :
Can't wait until they announce their financial results
Posted by keithsan on :
yep should be great news.
Posted by BuyTex on :
looks like a good one here...
Posted by keithsan on :
HOLY DIPPAGE BATMAN!!!
Gonna try and grab some on the bid.average down WTF.
Posted by stockfever on :
i will be looking to add also
Posted by Raptorsrule on :
I've got a bid in at .16....
Posted by stockfever on :
better move up bid to 0.17...MMs are outbidding
Posted by stockfever on :
make that 0.175. lol
Posted by stockfever on :
i was just gonna hit ask at 0.18...gone now
Posted by keithsan on :
.17 x .21
Posted by Raptorsrule on :
new HOD.....20.9..moving up during lunch...hmmmm
Posted by Danny12345 on :
just got filled. THanks and gl
Posted by Phoenixx on :
In at .17
Posted by Raptorsrule on :
bought more at .16 on the bid
Posted by Phoenixx on :
quote:Originally posted by Raptorsrule: bought more at .16 on the bid
I tried to get filled at .16...didnt happen though. In fact I stepped it up in increments all the way to .17 and it still didnt happen. Finally cancelled my order and resubmitted and they took it instantly.
Posted by MoneyMoneyMoney on :
I'm in. 5000 X .19 and 5000 X .17
Gl all.
Posted by Poker Time on :
OTC....Better think twice
Posted by Poker Time on :
last 16 cents
Posted by Raptorsrule on :
quote:Originally posted by Poker Time: OTC....Better think twice
LOL
Posted by Poker Time on :
It's a gift, You will thank me later..hehe
Posted by Poker Time on :
15 cents now.....oops
Posted by Raptorsrule on :
whatever dude....been trading OTCs for years...and yeah...I make money at it...
Posted by Poker Time on :
Awesome..You the man!
Posted by <DWS> on :
Looks like two negative comments in a row across the board. Come now..... why the hate?
Posted by Poker Time on :
There's always Barber college..hehe
Posted by keithsan on :
i'm on the bid at .13, .13 x .17
Posted by Phoenixx on :
Back to .15 x .17 now.
Posted by stockfever on :
RSI 29...looking to bounce...also with financials coming soon.
Posted by keithsan on :
looked at adding, had buys in at .13 and .155 but no luck.
Posted by keithsan on :
no volume should meant the seller is gone. Not hitting the bid today.
gonna watch for a while and maybe try and buy at the bid
Posted by Phoenixx on :
Bid creeping up.
Now .155 x .17
Posted by stockfever on :
.16 x .17 Now
Posted by stockfever on :
bid and ask the same
Posted by keithsan on :
.165 x .165 big buy listed for ARCA 150 VFIN was the dumper last 2 days hes on ask. no buys or sells tho
Posted by keithsan on :
nice VFIN backed up, not far enough tho.
2 on bid now.
Posted by Raptorsrule on :
looking better....
Posted by stockfever on :
moving now 0.165 x 0.19
Posted by Danny12345 on :
yep....
Posted by keithsan on :
yep VFIN Gone
Posted by Raptorsrule on :
.19
Posted by rider3160 on :
this looks like it is going
Posted by stockfever on :
This stock trades weird.
Posted by keithsan on :
yep.
VFIN dropped back to .25 before the close. Hope he stays there.
Posted by Triumph1902 on :
Wow that was alot of shares trading at the end...SCHB is on top of this one. Hopefully it has found its bottom and we can go up from here.
Posted by stockfever on :
Yeah, i don't get it...where did all this volume come from....the average volume was 38000 shares. Today 520k
Posted by keithsan on :
.16 x .163 2x1 vfin no where to be found...
Posted by Danny12345 on :
wow this thing is going down low... gonna grab me some more of this.
Posted by keithsan on :
quote:Originally posted by Danny12345: wow this thing is going down low... gonna grab me some more of this.
was thinking the same thing, i'm gonna average down at somepoint.
worried a bout VFIN selling. currently he's off the ask, looks like other traders trying to cut losses.
Posted by Phoenixx on :
<sigh>
Posted by Danny12345 on :
added some more at .13 Posted by keithsan on :
quote:Originally posted by Phoenixx: <sigh>
I second that.
Posted by binnocent on :
Any thoughts on this one....anyone still holding?
They seem very consistant on their quarterly report releases.....so should be next week!
Thanks,
Bob
Posted by dishgal1 on :
I'm still in. Hoping for a run soon.
Posted by Danny12345 on :
same here. Still holding strong
Posted by keithsan on :
holding here should be releasing good 4th quarter results, don't see a reason to sell yet.
Posted by binnocent on :
Thanks all !!!!! Holding as well.
Posted by keithsan on :
.15 x .164 some bid upticks. no vfin
Posted by Phoenix on :
Huge spread atm -- .125 x .18
Posted by Phoenix on :
.15 x .18 now..
Posted by Danny12345 on :
yep yep ... we are gonna move soon. Put on your seatbelt Posted by Danny12345 on :
.16x.17 Posted by Veatsol on :
Up 13%
0.15 X 0.18
Posted by keithsan on :
.13 x .19 nice size on the bid. need to tighten it up tho...
Posted by Danny12345 on :
that's a huge gap
Posted by keithsan on :
yep, i dont think they're showing true bids some buys at .19 and .17
Posted by keithsan on :
.175 x .19 a bit of volume now.
Posted by Danny12345 on :
.175x.19 now??
Posted by keithsan on :
quote:Originally posted by Danny12345: .175x.19 now??
bid and ask.
Posted by Danny12345 on :
yeah i know heh. I posted the same time as you posted urs.
Posted by keithsan on :
thought you did, was wondering about the ?'s was all.
big spread again, theyve done this before, jump in and out on bid, sometimes showing sometimes not.
Posted by keithsan on :
.125 x .20
Posted by Phoenix on :
Do you think the MMs could get this spread just a little bit wider?
/sarcasm
Posted by keithsan on :
LOL ya and yesterday was all buys, they threw a teeny little sell in at the end for .16 making the chart look awful.
Posted by Danny12345 on :
lol damn damn my porfolio looks awful....
Posted by keithsan on :
Bids over the High of the Day.
Posted by keithsan on :
Nice News:
FT. MYERS, Fla., Jan. 25 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM.OB - News) today announced that it had reached agreements for up to $600,000 of new equity financing for the Company as well as planned amendments to its credit facility. As part of these agreements, a new investor to the Company has purchased 2.0 million restricted shares of the Company's common stock at a purchase price $0.20/share, which has resulted in $400,000 of new equity capital coming into the Company.This investor was also granted a warrant to purchase 900,000 shares of common stock at an exercise price of $0.26/share As part of the equity agreements and planned credit facility amendment, the Company also granted the right to purchase an additional $200,000 of equity under the same terms by April 30, 2006 to Aspen Select Healthcare, LP ("Aspen") the Company's largest shareholder and creditor, provided that if Aspen elects not to exercise such rights, then the Company may make such shares available for purchase to the new investor. This investor was also granted a warrant to purchase 900,000 shares of common stock at an exercise price of $0.26/share
[ January 25, 2006, 08:31: Message edited by: keithsan ]
Posted by binnocent on :
A good PR....another good piece:
Mr. Gasparini added, "Operationally, the Company is doing great. We are experiencing very strong growth across the board in all our core testing services. While we are still completing our year-end audit and won't be releasing our 2005 fourth quarter and fiscal year financial results until late February or early March, I can report that after a record Q2 and Q3, our testing volumes increased another 23% in the fourth quarter of 2005 from the third quarter. In addition, we are experiencing very strong growth this month and expect that our testing volumes will increase another 15-20% sequentially from December. Given our current momentum, we anticipate that we will be profitable on a monthly basis by the end of the first quarter, and we believe this will be the final financing package for our current business plan."
A more complete description of the terms of these financings is included with the Company's report on Form 8-K, which was filed with the SEC yesterday.
Posted by Danny12345 on :
this thing has no volume for the past 2 days. ZZZZZZZZ
Posted by keithsan on :
.14 x .19 spread is to big, once it tightens back up volume will come. nice news today to.
Posted by keithsan on :
.16 x .19 no one selling on the bid.
Posted by Danny12345 on :
heh is that you bidding that .16? hehe j/k
Posted by keithsan on :
no actually I'm really pissed i didnt buy at .13 the other day though.
Posted by Danny12345 on :
.16x.18 nice
Posted by keithsan on :
.17 x .25 even nicer.
Posted by Danny12345 on :
heh i think some people just saw the news from yesterday
Posted by keithsan on :
.20 x .22 as long as VFIN doesn't show up were good
Posted by Phoenix on :
Sweet!
Posted by Danny12345 on :
.2 x .23
Posted by keithsan on :
LOL mm's dance. UBSS is sick of holding his shares and Nite trying to get them as cheap as possible.
Posted by Danny12345 on :
back to .18x.2
Posted by Phoenix on :
I got out at .21, which was probably a mistake, especially since it doesnt cover some of my earlier losses in other stocks.
Trying to buy again on the bid, but probably unlikely to happen.
Posted by Danny12345 on :
i am staying for a more gain. I know this thing has a huge potential.
Posted by Jelly on :
I'm just kicking myself for not averaging down. LOL
Posted by bdgee on :
I sniped some at 0.184 when the sales was at 0.21....0.24 now......yeeeeHAAAAA
Posted by keithsan on :
Nice one BDGEE, Jelly I didnt average down either, very unusual for me but I didn't like the way VFIN sold shares when we first played it.
Great news yesterday. Exactly what we talked about happening in the profile.
I'm still holding. and i'm actually green today.
Posted by Jelly on :
I'm green too, but if I averaged down, I'd be WAY more green LOL
Posted by Danny12345 on :
lol glad we are all green.
Posted by Phoenix on :
Yeah, thanks for the pick, Keithsan. Posted by keithsan on :
quote:Originally posted by Phoenix: Yeah, thanks for the pick, Keithsan.
hasn't done anything yet, unless you bought after me of course. up 50% today not bad.
Posted by Phoenix on :
Yeah I was in at .17
Posted by Raptorsrule on :
yay I'm green!....nice volume!
Posted by keithsan on :
2 by 1 .20 x .22
Posted by MoneyMoneyMoney on :
I'm green. Thanks keithsan...
I did not average either but its still nice to turn up.
Gl to you all
Posted by Phoenix on :
.16 x .18 NITE on bid, VFIN on ask.
Trying to get more at .17
Next ask is .23...hmmm.
Posted by Phoenix on :
Got filled at .17 when VFIN dropped the ask ; he's moved back to .18
Posted by keithsan on :
I don't like VFIN on this stock. He's a problem would like to see him back at .30
Posted by Phoenix on :
I agree..I'm back in at my original price, but I wish he hadnt been on the ask.
Posted by Danny12345 on :
without him we would've been flying by now heh
Posted by Phoenix on :
Yeah...I'm hoping he's gone soon so we can move up again.
Posted by Danny12345 on :
.15x.19
Posted by Phoenix on :
VFIN off the ask
.15/.20 now
Posted by Danny12345 on :
.19x.21
Posted by Phoenix on :
SACM has joined the bid at .17
Crap, it all moved up...well I'm out at .20 now, lol
My stupid Scottrade streamer wouldnt launch, grrrr
Oh well Posted by keithsan on :
.20 x.21 vfin at .40
Posted by Phoenix on :
Yeah, wish I had been able to alter my order in time -- but I'm not gonna complain too much -- maybe I'll get another re-entry point.
Posted by binnocent on :
Somebody needs to wake this sleeping beauty....lol
Really dead the last few days.....
Posted by keithsan on :
yep but she's been upticking slowly, someones trying to accumulate at lows....
Posted by keithsan on :
well hes moving those bids up.
.20 x .22 now...
Posted by keithsan on :
.21 x .22
Posted by Julia28 on :
PMED looking good this morning
Posted by Julia28 on :
Oh sorry...wrong thread...don't know how that happened...LOL
Posted by keithsan on :
yes it does Just riding freebies now....
Posted by Danny12345 on :
nice .24
Posted by keithsan on :
yep .21 x .24 some of that good news should be coming...
Posted by keithsan on :
HOD .26
bid 27 x ask .30
she gonna burn....
took long enough.
Posted by keithsan on :
.31 x .35
Posted by Danny12345 on :
holy cow .3x.38 this cow is flying lol
Posted by binnocent on :
Dang!!! I wasn't able to be around the computor this morning. Had a sell order * .24, It looked like a big wall * .25. Oh well made a profit. Can't complain!! Thanks Keithsan, nice pick!
Bob
Posted by keithsan on :
no problem glad you made money, should keep going though, look over the dd i provided when posted.....
Posted by keithsan on :
.40 Posted by binnocent on :
I know your picks are usually very good...I guess I was just getting a little worried cause it was taking so long to let loose. But that's usually my story.
Awesome run today!!!!
Posted by keithsan on :
quote:Originally posted by binnocent: I know your picks are usually very good...I guess I was just getting a little worried cause it was taking so long to let loose. But that's usually my story.
Awesome run today!!!!
I buy at or near the bottoms and hold (as long as I think its good) a few big runners more than pays for the one or 2 who never move.
Posted by keithsan on :
.30 x .39
Posted by keithsan on :
.30 x .33
Posted by eox on :
.30 x .35
Posted by jordanreed on :
thought i'd bring this up again...
spotted it on a filter...
nice trend since keith called it
Posted by jordanreed on :
NeoGenomics Announces Results for Third Quarter of FY 2006 7:00a ET November 10, 2006 (PR NewsWire) NeoGenomics, Inc. (OTC Bulletin Board: NGNM) today announced its results for the third quarter of fiscal year 2006. Significant accomplishments during the quarter included the following:
3rd Quarter 2006 Accomplishments: -- 186% year-over-year increase in revenues in Q3 '06 vs. Q3 '05 -- 316% increase in the nine months YTD revenue vs. the same period in '05 -- Increased gross margin to 55% in Q3 '06 from 46% in Q3 '05 -- Unveiled comprehensive Genetic Pathology Solutions (GPS) service offering -- Opened a new laboratory facility in Southern California -- Appointed Dr. Frank Yang, M.D., Ph.D. as Associate Medical Director -- Appointed Dr. Matthew Moore, Ph.D. as Vice President, Research & Development
President and Chief Scientific Officer Robert Gasparini said, "During the third quarter, we made significant strides in increasing our capacity, attracting key personnel and broadening our product lines which we believe will position NeoGenomics for a robust FY 2007. With respect to capacity, I am pleased to report that we finished the expansion of our 9,600 square foot facility here in Ft. Myers, FL and the build-out of our new 5,400 square foot facility in Nashville, TN. We have also been able to more than triple our Nashville staff since purchasing the lab in April of this year. In July, we opened our third laboratory facility in Southern California, which is currently going through the CA laboratory and genetics licensure process. This facility, which now gives us a bi-coastal presence, is expected to begin producing revenue sometime in the first quarter of FY 2007."
Gasparini went on to say, "One of the toughest challenges in growing a laboratory rapidly is the choreography and balance needed between building-out capacity and increasing the sales force. As a result of increasing our physical infrastructure in the third quarter, it gave us the flexibility to hire additional sales personnel. I am pleased to report that effective November 1st, we added four additional senior sales personnel to the NeoGenomics team. This has effectively doubled the size of our sales force. All four of these individuals were previously top-ranked sales personnel at another laboratory and I have personally worked with each of them prior to my joining NeoGenomics. We are now ready to drive revenue growth through the sales organization and are excited about what these individuals bring to the table."
Gasparini further stated, "In addition to increasing our capacity and expanding the sales force, we made other key hires during Q3. Dr. Matthew Moore joined us in July and was recently appointed to the position of Vice President, Research & Development. Dr. Moore has a Ph.D. in molecular biology and has significant experience in developing assays for use in genetic and molecular diagnostic testing. He has been charged with leading NeoGenomics' entry into the rapidly growing Contract Research Organization (CRO) marketplace during FY '07. We believe that we can offer many of the same services we perform for our diagnostic testing clients to other organizations engaged in pharmaceutical research and development with only modest incremental investments in our infrastructure, and we are excited to further diversify our revenue stream. As part of Dr. Moore's duties he will also begin assessing how we can introduce intellectual property into our business model."
"We also welcomed Dr. Frank Yang, a noted hematopathologist, to our team in late July as Associate Medical Director," Gasparini continued. "After his arrival, we were able to bring several critical anatomic pathology (AP) testing services in-house, which allowed us to launch our industry-leading Genetic Pathology Solutions (GPS) service offering in early September. Thus far, we are encouraged with the marketplace acceptance of these new services and we are seeing significant demand for them in the hematology/oncology segment. As we discussed in our September 26th press release announcing GPS, our customer mix began to evolve during the third quarter. In particular, we began to see more demand from higher margin oncology and hematology clients and reduced demand from some lower margin reference lab customers, primarily due to their perception that our new AP services conflict with some of their own services. This was an expected development, and we believe that any lost revenue from reference lab customers will be more than offset by new revenue from higher margin oncology and hematology clients which are a far more stable source of revenue for NeoGenomics over the longer term."
Gasparini finished by saying, "I am also pleased to report that in addition to the above new hires, Mr. Jerome Dvonch, the Company's Director of Finance, has been appointed as the Principal Accounting Officer of NeoGenomics. Jerry has worked tirelessly behind the scenes to ensure that our financial operations run smoothly and in this new capacity, he will assume primary responsibility for reporting of our financial information. Steven Jones, a member of our Board of Directors, will remain our Acting Principle Financial Officer, but will begin to focus more on strategic activities on behalf of the Company."
Steven Jones, the Acting Principle Financial Officer, said, "We are very pleased with our third quarter results. We were able to increase revenues by approximately 186% on a year-over-year basis to $1,602,000 in Q3 '06 from $559,000 in Q3 '05. This year-over-year increase was largely a result of a 160% increase in the number of tests performed as well as a 10% increase in our average revenue per test during this period. Our requisitions increased 162% to 2,398 in Q3 '06 from 917 requisitions in Q3 '05. Further highlighting our economies of scale is the fact that gross profit grew 242% on a year-over- year basis from Q3 '05 to Q3 '06, whereas selling, general and administrative expenses increased by only 76% during this period. As a result of these factors, our net income increased by approximately $271,800 to approximately $32,000 in Q3 '06 from a net loss of $239,900 in Q3 '05."
Jones continued, "With respect to our sequential growth rates, it is important to remember that, like all laboratories, we always experience some seasonality in our "same customer sales" during Q3 due to a larger than normal number of our customers and their patients taking vacations during these months. At NeoGenomics, this trend is further exacerbated in our Florida customer base as result of the yearly migration of a significant number of senior citizens back to northern climates during the hot summer months. Our sequential growth rate in this third quarter was also impacted by the aforementioned evolution of our customer mix as a result of introducing our new AP services. This evolution, which we consider to be a one-time event, resulted in a decrease of approximately $400,000 in revenues from certain reference lab customers during Q3 as compared to Q2. Based on our October results, we can report that revenues from reference lab customers have normalized and have begun to grow once again. In fact, our industry-leading turn-around times attracted a new reference lab customer in October and we are currently in discussions with others."
Jones went on to say, "We are issuing the following preliminary guidance for FY '07 at this time. Based on our current momentum and business plan, we believe we can achieve FY '07 revenue of approximately $14.0-$16.0 million and maintain gross margins in the 55% area. We also believe we can achieve net income in the range of $1.3 - $1.7 million. We expect capital expenditures to be approximately $1.0 - $1.5 million in FY '07 and we believe that we can lease finance a large portion of these. It is important to emphasize that the above guidance is based only on organic growth in our current business, and we reserve the right to adjust this guidance at any time as a result of acquisitions or other strategic initiatives we may undertake and/or based on the ongoing execution of our business plan. By no means should these estimates be construed as a guarantee of future performance, and current and prospective investors are encouraged to perform their own due diligence before buying or selling any of our securities."
Jones finished by saying, "We are also pleased to announce that NeoGenomics has been invited to make a presentation to investors at the JP Morgan Small Cap Conference next Wednesday, November 15th at 2:05 PM EST at the Four Seasons Hotel in Boston. It is a great honor to have been selected for such a prestigious conference and we look forward to sharing our story with the institutional investment community." Interested parties can listen to a web-cast of this presentation at http://www.mapdigital.com/jpmorgan/smallcapboston06/. An archive of this web- cast will also be available for 3 months.
The Company has also scheduled a web-cast and conference call to discuss these third quarter results on Friday, November 10, at 10:00 AM EST. Interested investors should dial (877) 407-0778 (domestic) and (201) 689-8565 (international) at least five minutes prior to the call. A replay of the conference call will be available until November 24, 2006 until 11:59 PM and can be accessed by dialing (877) 660-6853 (domestic) and (201) 612-7415 (international). The playback account number will be 286 and the playback pin number is 208851. The web-cast may be accessed under the Investor Relations section of the NeoGenomics website at http://www.neogenomics.org or at http://www.hawkassociates.com/ngnmmore.aspx. An archive of the web-cast will be available until 11:59 PM EST on March 2, 2007.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's cancer genetic testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Ft. Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Ft. Myers and services the needs of oncologists, pathologists, urologists, hospitals and other reference laboratories throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org.
Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements, including, but not limited to, the Company has incurred significant losses since its inception and has experienced negative operating margins and negative cash flows from operations, any adverse effect or limitations caused by governmental regulations, the company's ability to attract and retain qualified personnel, to initiate and develop client relationships, to gain market acceptance of service offerings, as well as other risks described from time to time in the company's filings with the Securities and Exchange Commission. Although the Company has used its best efforts to be accurate in making those forward-looking statements, there can be no assurance that the assumptions made by management will materialize. In addition, the information set forth in the Company's Form 10-KSB for the fiscal year ended December 31, 2005 describe certain additional risks and uncertainties that could cause actual results to vary materially from the future results covered in such forward-looking statements. The company undertakes no obligation to publicly revise or update the forward-looking statements to reflect new information, subsequent events or otherwise.
NeoGenomics, Inc. CONSOLIDATED BALANCE SHEET AS OF September 30, 2006 (unaudited) ASSETS CURRENT ASSETS: Cash and cash equivalents $411,613 Accounts receivable (net of allowance for doubtful accounts of $47,511) 1,136,335 Inventories 59,421 Other current assets 160,130 Total current assets 1,767,499 PROPERTY AND EQUIPMENT (net of accumulated depreciation of $420,190) 1,170,687 OTHER ASSETS 33,169 TOTAL $2,971,355 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $401,860 Deferred revenue 89,970 Short-term portion of equipment lease and notes payable 72,368 Accrued compensation 170,748 Accrued and other liabilities 65,580 Total current liabilities 800,526 LONG TERM LIABILITIES: Line of credit (net of unamortized discount of $52,757) 1,572,243 Long-term portion of equipment lease 371,634 Total long term liabilities 1,943,877 TOTAL LIABILITIES 2,744,403 STOCKHOLDERS' EQUITY: Common stock, $.001 par value, 100,000,000 shares authorized; 26,777,842 shares issued and outstanding 26,778 Additional paid-in capital 11,031,760 Deferred Stock Compensation (110,771) Accumulated equity (10,720,815) Total stockholders' equity 226,952 TOTAL $2,971,355 NeoGenomics, Inc. CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) For the For the For the For the Nine- Nine- Nine- Nine- Months Months Months Months Ended Ended Ended Ended September September September September 30, 2006 30, 2005 30, 2006 30, 2005 REVENUE $4,713,172 $1,134,429 $1,601,880 $559,349 COST OF REVENUE 2,023,479 648,491 720,866 301,486 GROSS PROFIT 2,689,693 485,938 881,014 257,863 OPERATING EXPENSES: Selling, general and administrative 2,158,471 981,561 765,687 436,160 Total operating expenses 2,158,471 981,561 765,687 436,160 OPERATING INCOME (LOSS) $531,222 $(495,623) $115,327 $(178,297) OTHER (INCOME)EXPENSE, NET: Interest Expense 231,638 140,845 83,432 61,640 Total Other (Income) Expense, Net 231,638 140,845 83,432 61,640 NET INCOME (LOSS) $299,584 $(636,468) $31,895 $(239,937) NET INCOME (LOSS) PER SHARE: Basic $0.01 $(0.03) $0.00 $(0.01) Diluted $0.01 $(0.03) $0.00 $(0.01) WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING : Basic 25,891,331 22,145,593 26,599,981 22,526,370 Diluted 29,318,402 22,145,593 31,172,953 22,526,370 NeoGenomics, Inc. CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) For the For the Nine-Months Nine-Months Ended Ended September 30, September 30, 2006 2005 CASH FLOWS FROM OPERATING ACTIVITIES: Net income (loss) $299,584 $(636,468) Adjustments to reconcile net income (loss) to net cash used in operating activities: Depreciation 158,879 88,335 Equity-based compensation 77,250 98,491 Provision for bad debts 212,058 65,727 Amortization of debt issue costs 16,076 13,973 Amortization of lease cap costs 362 - Amortization of relocation expenses 38,488 14,009 Changes in assets and liabilities, net: Accounts receivables, net of write-offs (797,294) (383,326) Inventory 579 (29,244) Pre-paid expenses (92,495) (25,223) Other current assets (48,441) 3,474 Deposits (31,463) 1,500 Accounts payable and other liabilities (135,022) 104,160 NET CASH USED IN OPERATING ACTIVITIES (301,439) (684,592) CASH FLOWS USED IN INVESTING ACTIVITIES - Purchases of property and equipment (752,679) (82,659) CASH FLOWS FROM FINANCING ACTIVITIES: Advances from affiliates, net 125,000 620,451 Issuance of notes payable 92,905 - Repayment of notes payable (90,905) - Proceeds from capital lease 481,179 - Repayment of capital lease (36,499) - Debt issue costs - (53,587) Issuances of common stock, net of transaction expenses 883,107 164,662 NET CASH PROVIDED BY FINANCING ACTIVITIES 1,454,787 731,526 NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 400,669 (35,725) CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 10,944 112,548 CASH AND CASH EQUIVALENTS, END OF PERIOD $411,613 $76,823 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid $195,286 $89,834 Income taxes paid $- $- SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Equipment leased under capital lease 481,175 - NeoGenomics, Inc. Supplemental Information on Customer Requisitions Received and Tests Performed For the For the Nine-Months Nine-Months Ended Ended September September % Inc 30, 2006 30, 2005 (Dec) Requisitions Received (cases) 6,818 1,887 261.3% Number of Tests Performed 9,448 2,506 277.0% Avg. # of Tests / Requisition 1.38 1.33 4.3% Total Testing Revenue $4,713,172 $1,134,429 315.5% Avg Revenue/Requisition $691.28 $601.18 15.0% Avg Revenue/Test $498.85 $452.69 10.2% For the For the Three-Months Three-Months Ended Ended September September % Inc 30, 2006 30, 2005 (Dec) Requisitions Received (cases) 2,398 917 161.5% Number of Tests Performed 3,309 1,271 160.3% Avg. # of Tests / Requisition 1.38 1.38 (0.4)% Total Testing Revenue $1,601,880 $559,349 186.4% Avg Revenue/Requisition $668.01 $609.98 9.5% Avg Revenue/Test $484.10 $440.08 10.0%
SOURCE NeoGenomics, Inc.
Investor Relations: Steven C. Jones, Director of Investor Relations, of NeoGenomics, Inc., +1-239-325-2001, sjones*neogenomics.org; Frank N. Hawkins or Julie Marshall, both of Hawk and Associates, Inc. for NeoGenomics, Inc., +1-305-451-1888, info*hawkassociates.com http://www.neogenomics.org Posted by jordanreed on :
bought at 1.50...now 1.80
Posted by jordanreed on :
NeoGenomics IncOTC BB:NGNM Show MeSymbol Lookup 1.58 0.02 (1.25%) Buy Sell Set Triggers View Option Chain
Bid 1.50Ask 1.58 B/A Size 500 x 500 High 1.58 Low 1.50 Vol. 49,442 (Heavy) Latest News Press Releases Company Events
American Microcap Institute Maintains 'Strong Buy' on NeoGenomics 9:20a ET January 19, 2007 (PR NewsWire) The American Microcap Institute (AMI), a leading online resource for microcap investors and a division of Hawk Associates Inc., announced today that it issued an update to its analyst coverage on NeoGenomics, Inc. (OTC Bulletin Board: NGNM) based on the company's third quarter earnings.
NeoGenomics is an independent medical laboratory company specializing in genetic testing for cancer. AMI maintained its "strong buy" rating and set a price target range of $1.80 to $2.10 by the end of 2007. The third quarter of 2006 was NeoGenomics' third consecutive profitable quarter. Total revenues grew 186% year-over-year but decreased 9% on a sequential basis due to seasonality and a transition in customer base to higher margin clients. The company also announced a record number of new customers in Q3, the opening of a new lab in Irvine, Calif., and the introduction of a new genetic pathology solutions (GPS) testing service. Subsequent to the release of Q3 earnings, NeoGenomics also announced the launch of the industry's first tech-only FISH testing service for pathologists.
The third quarter analyst update and previous reports on the company can be accessed for free on the AMI Research website, http://www.amistockreports.com.
About AMI Research
AMI Research, a service of the American Microcap Institute, provides fundamental research on promising small companies that do not have traditional Wall Street analyst coverage. These detailed issuer-paid research reports provide investors with an in-depth understanding of a company and its technology, industry, business model, financials and growth prospects.
AMI Research does not accept payment of fees in company stock. Principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in AMI reports accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by the company is in any way related to the specific ratings or views contained in the report. Please read all disclosures and certifications in each report prior to investing. For more information, visit http://www.amistockreports.com.
About The American Microcap Institute (AMI)
The American Microcap Institute (AMI) is a leading online resource for microcap investors and a division of Hawk Associates Inc. AMI is dedicated to providing investors with timely and accurate information on companies trading under $10. The AMI website provides investors with a free stock watch list and information about featured microcaps, company headlines, 20-minute delayed Level II price quotes, email alerts, CEO interviews and research reports. No registration is required to access the site. For more information, visit http://www.americanmicrocaps.com.
About Hawk Associates Inc.
Hawk Associates, Inc. is a full-service national investor relations and financial media relations consulting firm serving clients nationwide as well as in China and Vietnam. Hawk Associates operates the American Microcap Institute website, http://www.americanmicrocaps.com. For more information about Hawk Associates, visit http://www.hawkassociates.com or contact Frank Hawkins or Julie Marshall at (305) 451-1888, e-mail: info*hawkassociates.com.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that offers cancer genetic diagnostic testing services including cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry and molecular genetic testing. NeoGenomics is headquartered in Fort Myers, Fla., and services the needs of oncologists, pathologists, urologists, hospitals and other reference laboratories not offering genetic testing throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org.
quote:Originally posted by keithsan: .191 x .23 right now. NGNM: NeoGenomics, Inc. is a clinical testing laboratory that offers genetic and molecular diagnostic testing services to the oncology and perinatology markets. NeoGenomics is headquartered in Fort Myers, FL and services the needs of oncologists, pathologists and hospitals throughout the United States. NGNM currently has an OS of 22,576,975;
This company released big news right at the end of the 3rd quarter of 2005. They do not issue a lot of news releases but they announce operational news right before the end of the quarter and we expect some for this quarter. In their last news release NGNM announced that they had begun some new testing. These results should come out in their 4th quarter filing. With the added testing, again the quarterly growth should be excellent.
Quote: "strong growth continued in the third quarter with testing volumes up over 65.3% during the quarter versus the second quarter of 2005 and up over 420% from the third quarter of 2004. NeoGenomics also announced that during the third quarter, it had begun testing operations in three new areas: breast cancer, bladder cancer and cervical cancer. "
February 27, 2007 11:34 AM ETNeoGenomics, Inc. Announces the Licensure of its California Laboratory Location and Schedules its Q4 06 Earnings Conference Calladvertisement
Related information E-mail this article Print-friendly version Discuss this articleStocks mentioned in this articleNEOGENOMICS INC (NGNM) Stock Quote, Chart, News All PRNewswire NewsFT. MYERS, Fla., Feb. 27 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM) announced today that it has received a laboratory license for its new Irvine, California laboratory location and has received certification for this laboratory under the Clinical Laboratory Improvement Act, as amended (CLIA) through inspection by the California Department of Health.
NeoGenomics President, Robert Gasparini, said, "I am delighted to report that as a result of obtaining our license, we can now commence revenue operations at this facility. Revenues will start out modest as we continue to hire staff for this location, but, over time, we believe that California and the surrounding markets will be substantial contributors to our revenue and earnings growth. As cancer is primarily a disease of the elderly, the cancer genetics industry tends to do very well in areas where there are high concentrations of senior citizens. Indeed, the marketplace in southern California is similar in many respects to the marketplace in southern Florida, where NeoGenomics already has a substantial presence. We are excited to bring our industry-leading turn-around-times to the oncologists, urologists, pathologists and hospitals in this market and are hopeful that our services will be as warmly received in California as they have been in all of our other locations."
In other news, NeoGenomics also announced that it would release its final Q4 FY 2006 and full year earnings on Wednesday, March 14, 2007. The Company has also scheduled a web-cast and conference call to discuss these results on March 14th, at 11:00 AM EST to discuss these results. Interested investors should dial (877) 407-0778 (domestic) and (201) 689-8565 (international) at least five minutes prior to the call. A replay of the conference call will be available until 11:59 PM on March 28, 2007 and can be accessed by dialing (877) 660-6853 (domestic) and (201) 612-7415 (international). The playback account number is 286 and the playback conference ID#/PIN# is 233199. The web-cast may be accessed under the Investor Relations section of the NeoGenomics website at http://www.neogenomics.org or at the website of our Investor Relations firm, Hawk Associates, at http://www.hawkassociates.com/ngnmmore.aspx or at http://www.vcall.com/IC/CEPage.asp?ID=114420. An archive of the web-cast will be available until 11:59 PM EST on June 11, 2007.
About NeoGenomics, Inc.
Posted by jordanreed on :
NeoGenomics President Featured in Exclusive Interview with WallSt.net 7:00a ET March 6, 2007 (PR NewsWire) On February 2, Bob Gasparini, President for NeoGenomics, Inc. (OTC Bulletin Board: NGNM) updated the investment community in an exclusive interview with www.wallst.net . Topics covered in the interview include an overview of the Company and the markets it serves, recent press releases, current capitalization, upcoming strategic and financial milestones.
To hear the interview in its entirety, visit www.wallst.net , and click on "Interviews." The interview can be accessed either by locating the company's ticker symbol under the appropriate exchange on the left-hand column of the "Interviews" section of the site, or by entering the company's ticker symbol in the Search Archive window.
About NeoGenomics, Inc.:
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org .
Posted by jordanreed on :
NeoGenomics Announces Results for the Fourth Quarter and Full Year FY 2006advertisement
All PRNewswire NewsFT. MYERS, Fla., March 14 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM) today announced its results for the fourth quarter and full year of fiscal 2006. Significant accomplishments during the fourth quarter and year included the following:
Fourth Quarter 2006 Accomplishments: -- 135% year-over-year increase in revenues in Q4 06 vs. Q4 05 -- 10% sequential increase in revenues in Q4 06 vs. Q3 06 -- The announcement of an industry first Tech-Only FISH product -- The doubling of our national sales-force Full Year 2006 Accomplishments: -- 243% increase in revenues during FY '06 vs. FY '05 -- Requisitions increased 221% to 9,563 requisitions in FY '06 from 2,982 in FY '05 -- Avg. Revenue/Requisition increased 7% to $677.19 in FY '06 from $632.23 in FY '05 -- Test volume increased 215% to 12,838 tests in FY '06 from 4,082 in FY '05 -- Avg. Revenue/Test increased 9% to $504.44 in FY '06 from $461.86 in FY '05 -- The acquisition of the Center for Cytogenetics in Nashville, TN -- The build-out of a NeoGenomics clinical laboratory facility in Irvine, CA -- The roll-out of our Genetic Pathology Service (GPS) productRobert Gasparini, the Company's President, stated, "2006 was a breakout year for NeoGenomics Laboratories. We expanded our geographic footprint into two new locations with the acquisition and expansion of our Tennessee facility and the investment in a new California laboratory location which just received its license in February. We now have a truly bi-coastal presence. We continue to actively pursue additional geographic locations and capacity to complete our national network of regional laboratories."
Posted by jordanreed on :
nice move today
Posted by jordanreed on :
NeoGenomics Announces Results for First Quarter of FY 2007
![[Smile]](smile.gif)